TY - JOUR
T1 - Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study
AU - Triggiani, Luca
AU - Mazzola, Rosario
AU - Magrini, Stefano Maria
AU - Ingrosso, Gianluca
AU - Borghetti, Paolo
AU - Trippa, Fabio
AU - Lancia, Andrea
AU - Detti, Beatrice
AU - Francolini, Giulio
AU - Matrone, Fabio
AU - Bortolus, Roberto
AU - Fanetti, Giuseppe
AU - Maranzano, Ernesto
AU - Pasqualetti, Francesco
AU - Paiar, Fabiola
AU - Bonù, Marco Lorenzo
AU - Magli, Alessandro
AU - Bruni, Alessio
AU - Mazzeo, Ercole
AU - Franzese, Ciro
AU - Scorsetti, Marta
AU - Alongi, Filippo
AU - Jereczek-Fossa, Barbara Alicja
AU - Ost, Piet
AU - Buglione, Michela
PY - 2019/12
Y1 - 2019/12
N2 - PURPOSE: Herein, we report the clinical outcomes of a multicenter study evaluating the role of SBRT in a cohort of patients affected by oligoprogressive castration-resistant prostate cancer (CRPC). MATERIALS AND METHODS: This is a retrospective multicenter observational study including eleven centers. Inclusion criteria of the current study were: (a) Karnofsky performance status > 80, (b) histologically proven diagnosis of PC, (c) 1-5 oligoprogressive metastases, defined as progressive disease at bone or nodes levels (detected by means of choline PET/CT or CT plus bone scan) during ADT, (d) serum testosterone level under 50 ng/ml during ADT, (e) controlled primary tumor, (f) patients treated with SBRT with a dose of at least 5 Gy per fraction to a biologically effective dose (BED) of at least 80 Gy using an alpha-to-beta ratio of 3 Gy, (g) at least 6 months of follow-up post-SBRT. RESULTS: Eighty-six patients for a total of 117 lesions were treated with SBRT. The median follow-up was 30.7 months (range 4-91 months). The median new metastasis-free survival after SBRT was 12.3 months (95% CI 5.5-19.1 months). One- and two-year distant progression-free survival was 52.3% and 33.7%, respectively. Twenty-six out of 86 patients underwent a second course of SBRT due to further oligoprogressive disease: This resulted in a median systemic treatment-free survival of 21.8 months (95% CI 17.8-25.8 months). One-year systemic treatment-free survival was 72.1%. CONCLUSION: SBRT appears to be a promising approach in oligoprogressive castration-resistant prostate cancer. Further investigations are warranted.
AB - PURPOSE: Herein, we report the clinical outcomes of a multicenter study evaluating the role of SBRT in a cohort of patients affected by oligoprogressive castration-resistant prostate cancer (CRPC). MATERIALS AND METHODS: This is a retrospective multicenter observational study including eleven centers. Inclusion criteria of the current study were: (a) Karnofsky performance status > 80, (b) histologically proven diagnosis of PC, (c) 1-5 oligoprogressive metastases, defined as progressive disease at bone or nodes levels (detected by means of choline PET/CT or CT plus bone scan) during ADT, (d) serum testosterone level under 50 ng/ml during ADT, (e) controlled primary tumor, (f) patients treated with SBRT with a dose of at least 5 Gy per fraction to a biologically effective dose (BED) of at least 80 Gy using an alpha-to-beta ratio of 3 Gy, (g) at least 6 months of follow-up post-SBRT. RESULTS: Eighty-six patients for a total of 117 lesions were treated with SBRT. The median follow-up was 30.7 months (range 4-91 months). The median new metastasis-free survival after SBRT was 12.3 months (95% CI 5.5-19.1 months). One- and two-year distant progression-free survival was 52.3% and 33.7%, respectively. Twenty-six out of 86 patients underwent a second course of SBRT due to further oligoprogressive disease: This resulted in a median systemic treatment-free survival of 21.8 months (95% CI 17.8-25.8 months). One-year systemic treatment-free survival was 72.1%. CONCLUSION: SBRT appears to be a promising approach in oligoprogressive castration-resistant prostate cancer. Further investigations are warranted.
KW - CRPC
KW - Metastasis-directed therapy
KW - Prostate cancer
KW - Radiotherapy
KW - SBRT
U2 - 10.1007/s00345-019-02717-7
DO - 10.1007/s00345-019-02717-7
M3 - Article
VL - 37
SP - 2631
EP - 2637
JO - World Journal of Urology
JF - World Journal of Urology
SN - 0724-4983
IS - 12
ER -